YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
European equities traded in the US as American depositary receipts were trending higher late Friday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium ne…
European equities traded in the US as American depositary receipts were trending lower late Wednesda PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
DBV Technologies S.A. Châtillon, France, September 29, 2026 DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years The BLA is supported by the results fro…
European equities traded in the US as American depositary receipts were tracking lower Wednesday mor PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
European equities traded in the US as American depositary receipts were heading lower late Friday mo PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
European equities traded in the US as American depositary receipts were heading lower late Tuesday m PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
European equities traded in the US as American depositary receipts opened the week tracking sharply PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium ne…
DBV Technologies S.A. Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of August 31, 2026 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE…
European equities traded in the US as American depositary receipts were trending lower in late Tuesd PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
European equities traded in the US as American depositary receipts started the week tracking modestl PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Châtillon, France, July 30, 2026 DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT) (th…
European equities traded in the US as American depositary receipts eased late Tuesday morning with t PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
The food allergy market landscape is advancing through a robust clinical pipeline, with key programs being developed by companies such as DBV Technologies (Viaskin [DBV712] Peanut Patch), Novartis (Remibrutinib), Aravax (PVX108), ALK-Abell…
European equities traded in the US as American depositary receipts were tracking higher late Wednesd PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Châtillon, France, le 17 juillet 2026 DBV Technologies dépose un prospectus relatif à son Programme At-The-Market (ATM) pour un montant pouvant atteindre 150 millions de dollars DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasd…
Châtillon, France, July 17, 2026 DBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of Sales DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT) (the “Company”), a late-stage biopha…
Châtillon, France, July 16, 2026 DBV Technologies Announces the Filing of its 2026 Half-Year Report ― Conditions for Accessing or Consulting the Report DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a la…
Châtillon, France, le 16 juillet 2026 DBV Technologies publie son Rapport Financier Semestriel 2026 ― Modalités de mise à disposition ou de consultation DBV Technologies (Euronext : DBV – ISIN : FR0010417345 - Nasdaq : DBVT), une entrepris…
The following companies are expected to report earnings after hours on 07/16/2026. Visit our Earnings Calendar for a full list of expected earnings releases. Netflix, Inc. (NFLX)is reporting for the quarter ending June 30, 2026. The broadc…
Informations Réglementées Châtillon, France, le 6 juillet (22 h 30 CET) 2026 Bilan semestriel du Contrat de Liquidité de DBV Technologies avec ODDO BHF DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq : DBVT), une entreprise…
AMF Regulated Information Châtillon, France, July 6, 2026 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmace…
DBV Technologies S.A. Châtillon, France, June 9, 2026 DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (t…
Châtillon, France, le 9 juin 2026 DBV Technologies révise sa participation à la 47ème conférence annuelle Global Healthcare organisée par Goldman Sachs DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Stock Market : DBVT – C…
Châtillon, France, June 9, 2026 DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “Company”), a late-…
Châtillon, France, le 8 juin (22 :30 CET) 2026 DBV Technologies présente de nouvelles données positives issues de l’étude de phase 3 VITESSE, et un aperçu de l’étude THRIVE récemment initiée à l’occasion du Congrès de l’EAACI 2026 Dans l'é…
Châtillon, France, June 8, 2026 DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026 In the Phase 3 VITESSE study, VIASKIN® Peanut Patch demonstrated statis…
DBV Technologies S.A. Châtillon, France, June 5, 2026 DBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “Com…
Châtillon, France, le 02 juin (22 :30 CEST) 2026 DBV Technologies annonce le screening du premier participant de l’étude clinique de phase 2 THRIVE pour le patch VIASKIN®Peanut chez les nourrissons âgés de 6 à 12 mois allergiques à l’arach…
Châtillon, France, June 2, 2026 DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy The study is evaluating the efficacy and saf…
Châtillon, France, 30 avril 2026 DBV Technologies publie ses résultats financiers du 1er trimestre 2026 Trésorerie et équivalents de trésorerie de 229 millions de dollars au 31 mars 2026, portant l’horizon de trésorerie jusqu’au second tri…
Châtillon, France, April 30, 2026 DBV Technologies Reports First Quarter 2026 Financial Results Reported cash and cash equivalents of $229 million as of March 31, 2026 —providing funding into the second quarter of 2027 following the full e…
European equities traded in the US as American depositary receipts were tracking higher late Tuesday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
* DBV Technologies press release [https://seekingalpha.com/pr/20453416-dbv-technologies-reports-full-year-2025-financial-results-and-business-update] (DBVT [https://seekingalpha.com/symbol/DBVT]): FY GAAP EPS of -$1.05. * On December 31, 2…
Châtillon, France, 26 mars 2026 DBV Technologies publie ses résultats financiers annuels 2025 et fait le point sur ses activités Poursuite des avancées du programme de développement clinique du patch VIASKIN® Peanut chez les jeunes enfants…
Châtillon, France, March 26, 2026 DBV Technologies Reports Full Year 2025 Financial Results and Business Update Continued advancing the VIASKIN® Peanut Patch clinical development programs in peanut-allergic toddlers (1 through 3 years old)…
Châtillon, France, le 24 mars (22 :30 CET) 2026 DBV Technologies intégrera les indices CAC Mid 60 et SBF 120 à l'issue de la révision annuelle d'Euronext Paris Les modifications sont entrées en vigueur le lundi 23 mars 2026, après la clôtu…